
This article was downloaded by: [The University of British Columbia] On: 17 June 2013, At: 18:27 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/lncn20</u>

Synthesis of 5-Substituted 2'-Deoxyuridine-5'- Phosphonate Analogues and Evaluation of their Antiviral Activity

Sara Van Poecke^a, Davy Sinnaeve^b, José C. Martins^b, Jan Balzarini^c & Serge Van Calenbergh^a

^a Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Gent, Belgium

^b NMR and Structure Analysis Unit, Department of Organic Chemistry, Ghent University, Gent, Belgium

^c Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

To cite this article: Sara Van Poecke , Davy Sinnaeve , José C. Martins , Jan Balzarini & Serge Van Calenbergh (2012): Synthesis of 5-Substituted 2'-Deoxyuridine-5'- Phosphonate Analogues and Evaluation of their Antiviral Activity, Nucleosides, Nucleotides and Nucleic Acids, 31:3, 256-272

To link to this article: <u>http://dx.doi.org/10.1080/15257770.2012.654876</u>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <u>http://www.tandfonline.com/page/terms-and-conditions</u>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.



SYNTHESIS OF 5-SUBSTITUTED 2'-DEOXYURIDINE-5'-PHOSPHONATE ANALOGUES AND EVALUATION OF THEIR ANTIVIRAL ACTIVITY

Sara Van Poecke,¹ Davy Sinnaeve,² José C. Martins,² Jan Balzarini,³ and Serge Van Calenbergh¹

¹Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Gent, Belgium ²NMR and Structure Analysis Unit, Department of Organic Chemistry, Ghent University, Gent, Belgium ³Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

□ A small series of 5-(hetero)aryl-modified nucleoside phosphonates was synthesized via an 8-step procedure including a Wittig reaction and Suzuki–Miyaura coupling. An unanticipated anomerization during phosphonate deprotection allowed us to isolate both anomers of the 5-substituted 2'-deoxy-uridine phosphonates and assess their antiviral activity against a broad panel of viruses.

Keywords Antiviral nucleoside analogues; pyrimidine modification; phosphonates; α -nucleosides; antiviral activity

INTRODUCTION

Antiviral drugs have become crucial in the management of several viral infections, including human HSV, HIV, HBV, HCV, and cytomegalovirus (HCMV) infections. Prominent among these drugs are nucleoside analogues, which can act as potent antiviral agents owing to their ability to inhibit viral polymerases.^[1] Many publications have discussed the synthesis and antiviral activity of 5-modified 2'-deoxyuridine analogues. Several substituents have been introduced at C-5, including alkoxymethyl groups,^[2] azoles,^[3] and alkyloximes.^[3] Several analogues proved moderately to highly

Address correspondence to Serge Van Calenbergh, Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Gent, Belgium. E-mail: serge.vancalenbergh@ugent.be

Received 4 October 2011; accepted 3 January 2012.

We thank the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) for providing a scholarship to SVP. The antiviral research was supported by the K.U.Leuven (GOA no. 10/14). We also thank Leen Ingels, Leentje Persoons, Frieda De Meyer, Anita Camps, Lies Van den Heurck, and Steven Carmans for technical assistance in the antiviral experiments; and Izet Karalic for assistance with the preparative HPLC purification.






FIGURE 1 2'-Deoxyuridine and envisaged analogues.

active against HSV. These results showed that modification at position 5 of 2'-deoxyuridine represents an interesting approach in the search for new antiherpes agents. However, relatively few examples of 5-(hetero)aryl-modified nucleosides with promising antiviral activity have been reported.^[4] This may be due to the fact that these nucleosides are not efficiently converted into their triphosphate form. The first step in this process, the phosphorylation of the nucleoside analogue into its 5'-monophosphate counterpart by nucleoside kinases, is often rate-limiting in the conversion to the active metabolite. One way to overcome this bottleneck is to devise prodrugs that are capable of delivering the nucleoside monophosphate intracellularly.^[5,6] Another approach to bypass the first phosphorylation step is to use phosphonate analogues that, after intracellular conversion into their corresponding diphosphophosphonate forms, can exhibit antiviral activities. This led us to investigate a small series of 2'-deoxyuridine analogues that combine different aromatic substituents at position 5 of the base with a 5'-methylene phosphonate group (Figure 1).

RESULTS AND DISCUSSION


The synthesis of a series of 5-(hetero) aryl-modified nucleoside phosphonates started from 3'-O-tert-butyldimethylsilyl-2'-deoxy- β -D-uridine^[7] and is depicted in Scheme 1. Conversion of nucleoside **6** to the vinylic phosphonate **7** was accomplished following the two-step procedure described by Cosyn et al.^[8] Catalytic hydrogenation of **7** in the presence of Pd/C afforded phosphonate **8**, which was selectively brominated at C-5 of the pyrimidine moiety using *N*-bromosuccinimide in DMF.^[9] Palladium-catalyzed crosscoupling with four commercial aryl and heteroaryl boronic acids gave access to **10–13**.^[10] After removing the silyl protecting group, deprotection of the phosphonate esters was performed using TMSBr in CH₂Cl₂. Concomitant anomerization during this last step resulted for each analogue in a 2:1 mixture of the α - and β -isomer that could be separated using RP-HPLC.





9

10-13



SCHEME 1 Synthesis of 5-modified 2'-deoxyuridine phosphonate analogues. Reagents and conditions: (a) 2'-lodoxybenzoic acid, CH₃CN, 80°C, 6 hours; (ii) [(diethoxyphosphinyl)methyl] triphenylphosphorane, DMSO, rt, 20 hours, 41% over 2 steps; (b) H₂, Pd/C, MeOH, rt, overnight, 97%; (c) NBS, DMF, rt, overnight, 49%; (d) R-B(OH)₂, Na₂CO₃, Pd(PPh₃)₄, DMF, H₂O, reflux, 4 hours, 75–91%; (e) 1M TBAF in THF, rt, 1 hour, 32–71%; (f) TMSBr, CH₂Cl₂, rt, overnight, 4–19%.

Stereochemical assignment of compound **1a** was based on the results of a ROESY experiment (Figure 2). A clear rOe contact between H-4' and H-2'b (proton down) and a much weaker interaction between H-6 and H-2'b proved that H-4' and H-6 were not positioned at the same side of the fura-nose ring. The β -configuration of the nucleobase was further established by the presence of a strong interaction between H-6 and H-5'a,b.





FIGURE 2 2D ROESY (500.13 MHz, 298.0 K) spectrum of compound 1a.

In an effort to synthesize the nonmodified 2'-deoxyuridine-5'phosphonate analogue, compound 8 was successively treated with a 1M TBAF solution in THF and TMSBr in CH_2Cl_2 (Scheme 2). In this case, attempts to separate the anomeric mixture using flash chromatography and RP-HPLC were unsuccessful. To avoid the anomerization issue, we attempted to deprotect 18 in the presence of TMSBr under different reaction conditions. Following the reaction via ³¹P NMR, it was observed that anomerization started immediately after addition of TMSBr. We learned by attempts at different temperatures that no reaction occurred under $-20^{\circ}C$ and that anomerization started simultaneously with the phosphonate hydrolysis, even at low temperature. Also, the addition of an acid scavenger (e.g., (trimethylsilyl)acetamide or 2,6-lutidine) could not prevent anomerization.^[11]



SCHEME 2 Synthesis of nonmodified 2'-deoxyuridine phosphonate analogue **5a**. Reagents and conditions: (a) 1M TBAF in THF, rt, 3 hours, 69%; (b) TMSBr, CH₂Cl₂, rt, overnight, 65%.

All compounds were evaluated for their antiviral activity against a broad panel of viruses, including HSV-1 (KOS), HSV-2 (G), vaccinia virus (VV), vesicular stomatitis virus (VSV), thymidine kinase deficient HSV-1 TK⁻ (KOS ACV^r), HCMV, and VZV in HEL (human embryonic lung) cell cultures; and HIV-1 (III_B) and HIV-2 (ROD) in human T-lymphocyte (CEM) cell cultures. The activities of the compounds were compared with reference antiviral drugs: brivudin, cidofovir, acyclovir and ganciclovir.

None of the tested compounds showed toxicity to any of the tested cell lines. However, the final compounds **1a-4a** and **1b-4b** failed to show antiviral activity against HSV-1, HSV-2, VV, VSV, HSV-1 TK,- and different VZV strains. Also, in the human T-lymphocyte (CEM) cell cultures, none of these compounds showed activity against HIV-1 or HIV-2. Very weak antiviral activity was observed for the β -analogue **3a** and the α -analogue **2b** against HCMV Davies and HCMV AD-169, respectively, whereas compounds 2a and 4a showed weak activity against both HCMV strains (Table 1). The most active compound of this series, analogue 2a, was at least 6 or 50 times less active than ganciclovir and cidofovir, respectively. The lack of biological activity of these derivatives might be attributed to several features, including 1) their inability to diffuse through the cell membrane; 2) their ineffective conversion to the corresponding diphosphophosphonate analogue; or 3) their weak affinity for the target polymerases and/or lack of incorporation into viral RNA. If uptake into the cell would be the bottleneck, converting the phosphonates to an appropriate prodrug form could be considered.

CONCLUSION

In conclusion, this study described the synthesis, structural analysis, and antiviral activity of a small series of 2'-deoxyuridine analogues that combine different aromatic substituents at position 5 of the base and a 5'-methylene

Compound	$\mathrm{EC}_{50}{}^{\mathrm{a}}~(\mu\mathrm{M})$				Cytotoxicity (µM)	
	HCMV AD-169	HCMV Davis	VZV OKA	VZV (TK ⁻) 07/1	Cell morphology ^b (MCC)	Cell growth ^c (CC ₅₀)
1a	>100	>100	>100	>100	>100	
2a	45	45	100	100	>100	>100
3a	>20	41	>20	>20	≥ 100	>100
4a	55	63	>100	>100	>100	100
1b	>100	>100	>100	>100	>100	
2b	45	>20	100	100	≥ 100	>100
3b	>100	>100	>100	>100	>100	
4b	>100	>100	>100	>100	>100	
Acyclovir			1.3	37	>440	
Brivudin			0.026	12	>300	
Ganciclovir	7.9	7.0			≥ 394	141
Cidofovir	0.67	0.95			≥ 317	63

TABLE 1 Antiviral activity and cytotoxicity of 5-modified 2'-deoxyuridine phosphonate analogues

 against different HCMV and VZV strains in HEL cell cultures

^aEffective concentration required to reduce virus-induced cytopathicity by 50%. Virus input was 100 plaque forming units (PFU).

^bMinimum cytotoxic concentration or compound concentration that caused a microscopically detectable alteration of cell morphology.

^c50%-Cytotoxic concentration or compound concentration required to reduce cell growth by 50%.

phosphonate modification at the sugar moiety. All compounds were synthesized via an 8-step procedure, featuring a Wittig reaction and Suzuki–Miyaura coupling. An unexpected anomerization during the last step of the synthesis allowed us to investigate the β - as well as the α -anomers of the corresponding phosphonates. None of these analogues exhibited significant antiviral activity.

EXPERIMENTAL

General Synthesis

All reagents were from standard commercial sources and of analytical grade. Precoated Merck silica gel F254 plates were purchased for TLC; spots were examined under ultraviolet light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray. Column chromatography was performed on silica gel (63–200 μ m, 60 Å, Biosolve, Valkenswaard, Netherlands). With the exception of the ¹³C NMR spectrum of compound **1a**, which was recorded on a 500 MHz Bruker DRX apparatus, all NMR spectra were determined using a Varian Mercury 300 MHz spectrometer. Chemical shifts are given in ppm (δ) relative to the residual solvent signals, which in the case of DMSO- d_6 were 2.54 ppm for ¹H and 40.5 ppm for ¹³C. Structural assignment was confirmed with COSY and DEPT. All signals assigned to hydroxyl groups were exchangeable with D₂O. Exact mass measurements were performed on a Waters LCT Premier XETM time of flight (TOF) mass spectrometer

equipped with a standard electrospray ionization (ESI) and modular Lock-Spray TM interface (Waters Corp., Milford, MA, USA). Samples were infused in a CH₃CN/water (1:1) mixture at 10 μ L/min.

1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-hex-5enofuranosyl]-uracil (7)

2'-Iodoxybenzoic acid (550 mg, 1.97 mmol) was added to a solution of 6 (449 mg, 1.31 mmol) in CH₃CN (12 mL) and the resulting suspension was stirred at 80° C for 6 hours. After cooling in an ice bath (15 minutes), the solid was removed by filtration and washed with cold CH₃CN. The solvent was evaporated and the residue was co-distilled with toluene. The residue was dissolved in anhydrous DMSO (3.4 mL) and freshly prepared [(diethoxyphosphinyl)methyl]triphenylphosphorane in DMSO (3.4 mL) was added. After 20 hours, the mixture was poured into water and extracted with CH_2Cl_2 . The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo. The residue was lyophilized to remove the remaining DMSO and purified on a silica gel column ($CH_2Cl_2/MeOH 98:2$) yielding 257 mg (41%) of **7** as a colourless solid. ¹H NMR (300 MHz, DMSO- d_6): δ 0.070 (6H, s, TBDMS), 0.87 (9H, s, TBDMS), 1.23 (6H, app dt, *J* = 1.5 Hz, *J* = 6.9 Hz, 2 x OCH₂CH₃), 2.13–2.22 (1H, m, H-2'a), 2.34–2.43 (1H, m, H-2'b), 3.92–4.03 (4H, m, 2 x OCH₂CH₃), 4.20–4.25 (1H, m, H-4'), 4.38–4.45 (1H, m, H-3'), 5.64 (1H, d, J = 7.8 Hz, CH=CH), 5.96–6.09 (1H, m, H-6'), 6.16 (1H, dd, J = 6.0 Hz, J = 7.5 Hz, H-1', 6.60-6.75 (1H, m, H-5'), 7.68 (1H, d, J = 8.4)Hz, CH=CH), 11.34 (1H, s, 3-NH). ³¹P NMR (DMSO- d_6): δ 17.21. ¹³C NMR $(75 \text{ MHz}, \text{DMSO-}d_6): \delta -5.02, -4.87 \text{ (TBDMS)}, 16.10, 16.18 \text{ (OCH}_2\text{CH}_3),$ 17.60 (TBDMS), 25.57 (TBDMS), 61.21, 61.31 (OCH₂CH₃), 74.36 (C-3'), 84.27 (C-1'), 85.27 (C-4', d, J = 23 Hz), 102.07 (C-5), 119.70 (C-6', d, J = 23 Hz) 182 Hz, 141.38 (C-6), 147.81 (C-5', d, J = 5 Hz), 150.29 (C-2), 162.98 (C-4). Exact mass (ESI-MS) for C₂₀H₃₆N₂O₇PSi [M+H]⁺ found, 475.2035; calcd, 475.2024.

1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-Dhexofuranosyl]-uracil (8)

To a solution of compound **7** (257 mg, 0.54 mmol) in MeOH (8 mL) was added 10% Pd/C. The reaction mixture was stirred under hydrogen atmosphere overnight. The catalyst was removed by filtration through Celite and the filtrate was evaporated to yield pure compound **8** (250 mg, 97%) as a colorless solid. ¹H NMR (300 MHz, DMSO- d_6): δ 0.084 (6H, app d, J = 2.4 Hz, TBDMS), 0.87 (9H, s, TBDMS), 1.22 (6H, t, J = 6.9 Hz, 2 x OCH_2CH_3), 1.65–1.86 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.00–2.15 (1H, m, H-2'a), 2.22–2.31 (1H, m, H-2'b), 3.68–3.72 (1H, m, H-3'), 3.92–4.04 (4H, m, 2 x OCH_2CH_3), 4.23–4.29 (1H, m, H-4'), 5.62 (1H, d, J = 8.1 Hz, CH=CH), 6.10 (1H, t, J = 6.6 Hz, H-1'), 7.59 (1H, d, J = 8.4 Hz, CH=CH), 11.32 (1H, s, 3-NH).³¹P NMR (DMSO- d_6): δ 31.72.¹³C NMR (75 MHz, DMSO- d_6):

 δ -5.04, -4.99 and -4.73 (TBDMS), 16.21 and 16.28 (OCH₂CH₃)₂, 17.58 (TBDMS), 20.97 (C-6', d, *J* = 139 Hz), 25.69 (C5', d, *J* = 12 Hz), 60.90, 60.97 (OCH₂CH₃)₂, 73.84 (C-3'), 84.95 (C-4', d, *J* = 16 Hz), 83.61 (C-1'), 102.10 (C-5), 141.03 (C-6), 150.40 (C-2), 163.11 (C-4). Exact mass (ESI-MS) for C₂₀H₃₈N₂O₇PSi [M+H]⁺ found, 477.2119; calcd, 477.2180.

1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-Dhexofuranosyl]-5-bromouracil (9)

To a solution of compound 8 (950 mg, 1.99 mmol) in DMF (15 mL) was added N-bromosuccinimide (NBS, 390 mg, 2.19 mmol) under N₂. The reaction mixture was stirred at room temperature for 16 hours. DMF was removed in vacuo and the residue was purified by column chromatography $(CH_2Cl_2/MeOH 97:3)$ to afford 9 (538 mg, 49%) as a white foam. ¹H NMR (300 MHz, CDCl₃): δ 0.082 (6H, app d, I = 1.8 Hz, TBDMS), 0.89 (9H, s, TBDMS), 1.34 (6H, t, I = 6.9 Hz, 2 x OCH_2CH_3), 1.82–2.02 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.09–2.16 (1H, m, H-2'a), 2.29–2.32 (1H, m, H-2'b), 3.81-3.84 (1H, m, H-4'), 4.07-4.19 (5H, m, 2 x OCH₂CH₃, H-3'), 6.13 (1H, t, I = 6.3 Hz, H-1'), 7.65 (1H, s, H-6), 9.83 (1H, s, 3-NH).³¹P NMR (CDCl₃): δ 30.90. ¹³C NMR (75 MHz, CDCl₃): δ -4.83, -4.56 (TBDMS), 16.46, 16.54 (OCH₂CH₃)₂, 17.89 (TBDMS), 22.33 (C-6', d, *J* = 143 Hz), 25.68 (TBDMS), 26.56 (C-5', d, J = 4.1 Hz), 40.85 (C-2'), 61.80, 61.83 (OCH₂CH₃)₂, 74.50 (C-3'), 85.57 (C-1'), 86.53 (C-4', d, I = 17.0 Hz), 97.10 (C-5), 139.01 (C-5)6), 149.47 (C-2), 159.03 (C-4). Exact mass (ESI-MS) for C₂₀H₃₇BrN₂O₇PSi [M+H]⁺ found, 555.1323; calcd, 555.1286.

General Procedure for the Synthesis of 5-Modified Nucleoside Phosphonates via Suzuki-Miyaura Coupling

A mixture of compound **9** (1 equiv.), aryl boronic acid (2 equiv.), $Pd(PPh_3)_4$ (0.1 equiv.) and Na_2CO_3 (3.3 equiv.) in DMF and degassed H_2O was heated (\pm 130°C, oil bath) under argon for 6 hours or until TLC indicated consumption of all starting material. The mixture was then concentrated and co-distilled with toluene. The residue was purified by column chromatography ($CH_2Cl_2/MeOH$ 94:6–98:2), affording the 5-modified analogues in moderate yield.

1-[3-O-tert-Butyldimethylsilyl-2, 5, 6-trideoxy-6-(diethoxyphosphinyl)- β -D-hexofuranosyl]-5-phenyluracil (10)

Reaction of compound **9** (153 mg, 0.27 mmol) with phenylboronic acid (68 mg, 0.55 mmol), Pd(PPh₃)₄ (32 mg, 0.027 mmol) and Na₂CO₃ (96 mg, 0.91 mmol) in DMF (6.5 mL) and degassed H₂O (0.8 mL) was performed as described in the general procedure to yield compound **10** as a colorless solid (120 mg, 79%). ¹H NMR (300 MHz, CDCl₃): δ 0.084 (6H, s, TBDMS), 0.90 (9H, s, TBDMS), 1.25–1.32 (6H,

263

m, 2 x *O*CH₂CH₃), 1.73–2.04 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.11–2.20 (1H, m, H-2'a), 2.31–2.39 (1H, m, H-2'b), 3.83–3.86 (1H, m, H-4'), 4.00–4.11 (5H, m, 2 x *O*CH₂CH₃ and H-3'), 6.23 (1H, app t, J = 6.6 Hz, H-1'), 7.33–7.71 (6H, m, Ph and H-6). ³¹P NMR (CDCl₃): δ 30.69. ¹³C NMR (75 MHz, CDCl₃): δ –4.73 and –4.46 (TBDMS), 16.48, 16.56 (OCH₂CH₃)₂, 18.00 (TBDMS), 22.39 (C-6', d, J = 143 Hz), 25.80 (TBDMS), 26.60 (C-5', d, J = 4.4 Hz), 40.67 (C-2'), 61.89 and 61.92 ((OCH₂CH₃)₂, d, J =6.5Hz, 74.75 (C-3'), 85.30 (C-1'), 86.42 (C-4', d, J = 17.0 Hz), 115.67 (C-5), 128.07–133.10 (Ph), 136.95 (C-6), 150.02 (C-2), 162.39 (C-4). Exact mass (ESI-MS) for C₂₆H₄₂N₂O₇PSi [M+H]⁺ found, 553.2485; calcd, 553.2493.

1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-Dhexofuranosyl]-5-(naphthalen-1-yl)uracil (11)

Reaction of compound 9 (122 mg, 0.22 mmol) with naphthalene-1boronic acid (75 mg, 0.44 mmol), $Pd(PPh_3)_4$ (25 mg, 0.022 mmol) and Na₂CO₃ (77 mg, 0.72 mmol) in DMF (5 mL) and degassed H₂O (0.7 mL) was performed as described in the general procedure to afford compound 11 as a colorless solid (120 mg, 91%). ¹H NMR (300 MHz, CDCl₃): δ 0.056 (6H, s, TBDMS), 0.87 (9H, s, TBDMS), 1.15–1.24 (6H, m, 2 x OCH₂CH₃), 1.77–2.03 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.12-2.18 (1H, m, H-2'a), 2.26-2.31 (1H, m, H-2'b), 3.82 (1H, app s, H-4'), 3.95–4.13 (5H, m, 2 x OCH₂CH₃ and H-3'), 6.24 (1H, app t, I = 6.6 Hz, H-1'), 7.42–7.82 (7H, m, naphthalene), 7.98 (1H, s, H-6), 8.43 (1H, s, 3-NH). ³¹P NMR (CDCl₃): δ 30.95. ¹³C NMR $(75 \text{ MHz}, \text{CDCl}_3): \delta -4.87 \text{ and } -4.62 \text{ (TBDMS)}, 16.2, 16.3 \text{ (OCH}_2\text{CH}_3),$ 17.85 (TBDMS), 22.26 (C-6', d, I = 143 Hz), 25.65 (TBDMS), 23.46 (C-5'), 40.50 (C-2'), 61.63, 61.71 (OCH₂CH₃), 74.63 (C-3'), 85.26 (C-1'), 86.29 (C-4', d, I = 17.0 Hz), 115.45 (C-5), 125.89-133.22 (naphthalene), 136.91(C-6), 149.88 (C-2), 162.26 (C-4). Exact mass (ESI-MS) for C₃₀H₄₄FN₂O₇PSi [M+H]⁺ found, 603.2675; calcd, 603.2650.

$1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-\beta-D-hexofuranosyl]-5-(4-fluorophenyl)uracil (12)$

Reaction of compound **9** (163 mg, 0.29 mmol) with 4fluorophenylboronic acid (82 mg, 0.59 mmol), Pd(PPh₃)₄ (34 mg, 0.029 mmol) and Na₂CO₃ (102 mg, 0.97 mmol) in DMF (7 mL) and degassed H₂O (0.9 mL) was performed as described in the general procedure to yield compound **12** as a colorless solid (141 mg, 84%). ¹H NMR (300 MHz, CDCl₃): δ 0.010 (6H, s, TBDMS), 0.80–0.84 (9H, m, TBDMS), 1.21 (6H, app q, J = 7.2 Hz, 2 x *O*CH₂CH₃), 1.68–1.94 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.02–2.11 (1H, m, H-2'a), 2.23–2.31 (1H, m, H-2'b), 3.74–3.78 (1H, m, H-4'), 3.93–4.02 (5H, m, 2 x *O*CH₂CH₃ and H-3'), 6.14 (1H, app t, J = 6.9 Hz, H-1'), 6.99–7.04 (2H, m, subs Ph), 7.34–7.42 (3H, m, subs Ph and H-6), 8.25 (1H, s, 3-NH). ³¹P NMR (CDCl₃): δ 30.74. ¹³C NMR (75 MHz, CDCl₃): δ -4.59, -4.33 (TBDMS), 16.64, 16.72 (OCH₂CH₃), 18.14 (TBDMS), 22.65 (C-6', d, J = 143 Hz), 25.91 (TBDMS), 26.89 (C-5', d, J = 5.0 Hz), 40.95 (C-2'), 61.89, 62.01 (OCH₂CH₃), 74.89 (C-3'), 85.60 (C-1'), 86.55 (C-4', d, J = 17 Hz), 115.00 (C-5), 128.42–132.40 (naphthalene), 136.74 (C-6), 149.55 (C-2), 161.72 (C-4). Exact mass (ESI-MS) for C₂₆H₄₁FN₂O₇PSi [M+H]⁺ found, 571.2430; calcd, 571.2399.

1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-Dhexofuranosyl]-5-(thiophen-2-yl)uracil (13)

Reaction of compound 9 (155 mg, 0.28 mmol) with thiophene-2-boronic acid (71 mg, 0.56 mmol), Pd(PPh₃)₄ (32 mg, 0.028 mmol) and Na₂CO₃ (98 mg, 0.92 mmol) in DMF (6.7 mL) and degassed H_2O (0.8 mL) was performed as described in the general procedure to yield compound 13 as a colorless solid (117 mg, 75%). ¹H NMR (300 MHz, $CDCl_3$): δ 0.090 (6H, s, TBDMS), 0.90 (9H, s, TBDMS), 1.26–1.37 (6H, m, 2 x OCH₂CH₃), 1.83–2.08 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.14–2.23 (1H, m, H-2'a), 2.32–2.40 (1H, m, H-2'b), 3.85–3.90 (1H, m, H-4'), 4.06–4.18 (5H, m, 2 x OCH_2CH_3 and H-3'), 6.23 (1H, app t, I = 6.3 Hz, H-1'), 7.01–7.04 (1H, m, thiophene), 7.25-7.29 (1H, m, thiophene), 7.39-7.44 (1H, m, thiophene), 7.69 (1H, s, H-6), 9.97 (1H, s, 3-NH). ³¹P NMR (CDCl₃): δ 30.80. ¹³C NMR (75 MHz, CDCl₃): δ -4.77 and -4.50 (TBDMS), 16.48, 16.56 (OCH₂CH₃), 17.95 (TBDMS), 22.36 (C-6', d, J = 143 Hz), 25.74 (TBDMS), 26.69 (C-5', d, I = 4.7 Hz), 40.91 (C-2'), 61.79, 61.86 (OCH₂CH₃), 74.64 (C-3'), 85.62 (C-1'), 86.55 (C-4', d, J = 16.8 Hz), 110.20 (C-5), 124.42, 125.37, 127.10 and 133.63 (thiophene), 134.32 (C-6), 149.39 (C-2), 161.27 (C-4). Exact mass (ESI-MS) for $C_{24}H_{40}N_2O_7PSSi [M+H]^+$ found, 559.2058; calcd, 559.2058.

1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5phenyluracil (14)

Compound **10** (115 mg, 0.21 mmol) was dissolved in THF (1.3 mL). A solution of 1 M TBAF in THF (0.46 mmol, 0.46 mL) was added. After stirring for 1 hour at room temperature, the reaction was completed. The solvent was evaporated and the dry residue was purified by column chromatography (CH₂Cl₂/MeOH 96:4) to give pure compound **14** (65 mg, colorless solid) in 71% yield. ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.18 (6H, dt, J = 1.8 Hz, J = 6.9 Hz, 2 x *O*CH₂CH₃), 1.75–1.83 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.06–2.14 (1H, m, H-2'a), 2.36–2.51 (1H, m, H-2'b), 3.71–3.72 (1H, m, H-4'), 3.89–3.99 (4H, m, 2 x *O*CH₂CH₃), 4.06–4.12 (1H, m, H-3'), 5.29 (1H, d, J = 4.5 Hz, 3'-OH), 6.17 (1H, t, J = 6.9 Hz, H-1'), 7.29–7.40 (3H, m, Ph), 7.51–7.54 (2H, m, Ph), 7.63 (1H, s, H-6). ³¹P NMR (DMSO-*d*₆): δ 31.80. ¹³C NMR (75 MHz, DMSO-*d*₆): δ 16.13, 16.20 (OCH₂CH₃), 21.20 (C-6', d, J = 139 Hz), 26.01 (C-5', d, J = 4.7 Hz),

60.82, 60.85 ((OCH₂CH₃)₂, 2d, J = 6.3 Hz)), 72.80 (C-3'), 84.46 (C-1'), 85.74 (C-4', d, J = 17.0 Hz), 113.07 (C-5), 114.76, 115.04, 129.29, 129.34, 130.23 and 130.34 (Ph), 137.87 (C-6), 149.89 (C-6), 162.05 (C-4). Exact mass (ESI-MS) for C₂₀H₂₈N₂O₇P [M+H]⁺ found: 439.1639, calcd: 439.1686.

1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-(naphthalen-1yl)-uracil (15)

Compound 11 (120 mg, 0.20 mmol) was deprotected using the same procedure as described for the synthesis of compound 14. Compound 15 was obtained as a colorless solid in a 65% yield (63 mg). ¹H NMR (300 MHz, CDCl₃): δ 1.17–1.25 (6H, m, 2 x OCH₂CH₃), 1.77–2.02 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.12–2.21 (1H, m, H-2'a), 2.40–2.53 (1H, m, H-2'b), 3.91–4.07 (5H, m, 2 x OCH₂CH₃ and H-4'), 4.16–4.20 (1H, m, H-3'), 5.28 (1H, s, 3'-OH), 6.26 (1H, t, I = 6.6 Hz, H-1'), 7.40-7.46 (2H, m, naphthalene), 7.53-7.58 (2H, m, naphthalene), 7.75–7.84 (3H, m, naphthalene), 7.96 (1H, s, H-6). ³¹P NMR (CDCl₃): δ 31.46. ¹³C NMR (75 MHz, CDCl₃): δ 16.41, 16.46 ((OCH₂CH₃)₂, d, I =5.9 Hz), 22.01 (C-6', d, J = 141 Hz), 26.66 (C-5'), 40.06 (C-2'), 61.99, $62.06 (OCH_2CH_3)_2$, 73.85 (C-3'), 85.43 (C-1'), 86.25 (C-4', d, J = 16.2 Hz), 115.60 (C-5), 126.03, 126.31, 126.36, 127.25, 127.62, 128.09, 128.30, 130.00, 132.88 and 133.34 (naphthalene), 137.17 (C-6), 150.29 (C-6), 162.61 (C-4). Exact mass (ESI-MS) for C₂₄H₃₀N₂O₇P [M+H]⁺ found: 489.1814, calcd: 489.1785.

1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-(4fluorophenyl)-uracil (16)

Compound **12** (135 mg, 0.24 mmol) was deprotected using the same procedure as described for the synthesis of compound **14**. Compound **16** was obtained as a colorless solid in a 32% yield (35 mg). ¹H NMR (300 MHz, DMSO- d_6): δ 1.18 (6H, dt, J = 2.4 Hz, J = 6.9 Hz, 2 x OCH_2CH_3), 1.70–1.82 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.05–2.13 (1H, m, H-2'a), 2.37–2.44 (1H, m, H-2'b), 3.70–3.71 (1H, m, H-4'), 3.89–3.99 (4H, m, 2 x OCH_2CH_3), 4.06–4.09 (1H, m, H-3'), 5.28 (1H, d, J = 4.5 Hz, 3'-OH), 6.16 (1H, t, J = 7.2 Hz, H-1'), 7.17–7.23 (2H, m, subs Ph), 7.55–7.60 (2H, m, subs Ph), 7.64 (1H, s, H-6), 11.53 (1H, s, 3-NH). ³¹P NMR (DMSO- d_6): δ 31.80. ¹³C NMR (75 MHz, DMSO- d_6): δ 16.2, 16.3 (OCH₂CH₃), 21.22 (C-6', d, J = 139 Hz), 26.11 (C-5', d, J = 5 Hz), 60.99, 61.95 ((OCH₂CH₃)₂, 2d, J = 6.1 Hz), 72.80 (C-3'), 84.61 (C-1'), 85.86 (C-4', d, J = 16.7 Hz), 113.07 (C-5), 114.76, 115.04, 129.29, 129.34, 130.23 and 130.34 (subs Ph), 137.87 (C-6), 149.89 (C-6), 162.05 (C-4). Exact mass (ESI-MS) for C₂₀H₂₇FN₂O₇P [M+H]⁺ found, 457.1547; calcd, 457.1534.

1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-(thiophen-2-yl)uracil (17)

Compound **13** (117 mg, 0.21 mmol) was deprotected using the same procedure as described for the synthesis of compound **14**. Compound **17** was obtained as a colorless solid in a 63% yield (59 mg). ¹H NMR (300 MHz, CDCl₃): δ 1.31 (6H, app dt, J = 2.1 Hz, J = 6.9 Hz, 2 x OCH_2CH_3), 1.86–2.08 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.18–2.27 (1H, m, H-2'a), 2.46–2.54 (1H, m, H-2'b), 3.97–3.98 (1H, m, H-4'), 4.04–4.15 (4H, m, 2 x OCH_2CH_3), 4.19–4.26 (1H, m, H-3'), 5.30 (1H, s, 3'-OH), 6.25 (1H, app t, J = 6.6 Hz, H-1'), 6.97–7.00 (1H, m, thiophene), 7.24 (1H, d, J = 4.8 Hz, thiophene), 7.36 (1H, d, J = 3.0 Hz, thiophene), 7.69 (1H, s, H-6). ³¹P NMR (CDCl₃): δ 31.48. ¹³C NMR (75 MHz, CDCl₃): δ 16.50, 16.58 (OCH₂CH₃)₂, 22.05 (C-6', d, J = 142 Hz), 26.67 (C-5'), 40.27 (C-2'), 62.07, 62.17 (OCH_2CH_3)₂, 73.80 (C-3'), 85.72 (C-1'), 86.40 (C-4', d, J = 15.9 Hz), 110.19 (C-5), 124.35, 125.45, 127.08 and 133.64 (thiophene), 134.55 (C-6), 149.77 (C-2), 161.52 (C-4). Exact mass (ESI-MS) for C₁₈H₂₆N₂O₇PS [M+H]⁺ found, 445.1210; calcd, 445.1193.

General Procedure for the Deprotection of 5-Modified Nucleoside Phosphonates

The phosphonic ester (1 equiv.) was dissolved in CH_2Cl_2 under argon. TMSBr (2 equiv.) was added and the resulting solution was stirred overnight. The solvent was evaporated and the residue dissolved in a mixture of EtOAc/Et₂O (1:1) and water. The organic phase was washed with water and the water layers were combined and lyophilized. Purification of the crude using RP-HPLC (Phenomenex Luna C-18, H₂O/0.1% HCOOH in CH₃CN, 90:10 \rightarrow 0:100 in 23 minutes, flow 17.5 mL/minute) afforded 2 series of compounds: the α - (retention time \geq 12 minutes) and β -isomer (retention time \approx 10–11 minutes) of each phosphonate.

1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-hexofuranosyl]-5-phenyl uracil (1a) and 1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-α-D-hexofuranosyl]-5-phenyluracil (1b)

Reaction of compound 14 (27 mg, 0.061 mmol) with TMSBr (16 μ L, 0.12 mmol) in CH₂Cl₂ (0.9 mL) as described in the general procedure affording the β - (1a, 0.9 mg, 4%) and α -isomer (1b, 3.2 mg, 14%) as white powders. Compound 1a: ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.52–1.55 (2H, m, H-6'a and H-6'b), 1.79–1.91 (2H, m, H-5'a and H-5'b), 2.07–2.11 (1H, m, H-2'a), 2.29–2.38 (1H, m, H-2'b), 3.73 (1H, app s, H-4'), 4.06 (1H, app s, H-3'), 6.14 (1H, t, *J* = 6.6 Hz, H-1'), 7.27–7.40 (3H, m, Ph), 7.51–7.54 (2H, m, Ph), 7.63 (1H, s, H-6). ³¹P NMR (DMSO-*d*₆): δ 24.44. ¹³C NMR (125 MHz, DMSO-*d*₆): δ 24.56 (C-6', d, *J* = 146 Hz), 27.22 (C-5'), 38.75 (C-2'), 72.76 (C-3'), 84.30 (C-1'), 86.57 (C-4', d, *J* = 19.3 Hz), 113.89 (C-5), 127.31 (para), 128.10 (ortho),

128.21 (meta), 132.91 (ipsa) (Ph), 137.58 (C-6), 149.86 (C-2), 162.08 (C-4). Exact mass (ESI-MS) for $C_{16}H_{18}N_2O_7P$ [M-H]⁻ found, 381.0836; calcd, 381.0857; Compound **1b**: ¹H NMR (300 MHz, DMSO- d_6): δ 1.49–1.57 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 1.98 (1H, app d, J = 14.1 Hz, H-2'a), 2.57–2.65 (1H, m, H-2'b), 4.11 (1H, app s, H-4'), 4.23 (H, app s, H-3'), 6.14 (1H, app d, J = 6.6 Hz, H-1'), 7.27–7.38 (3H, m, Ph), 7.51–7.54 (2H, m, Ph), 8.16 (1H, s, H-6). ³¹P NMR (DMSO- d_6): δ 23.62. Exact mass (ESI-MS) for $C_{16}H_{18}N_2O_7P$ [M-H]⁻ found, 381.0851; calcd, 381.0857.

1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-\B-D-hexofuranosyl]-5-(naphtalen-1yl)uracil (2a) and 1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-\D-Dhexofuranosyl]-5-(naphthalen-1-yl)uracil (2b)

Reaction of compound 15 (63 mg, 0.13 mmol) with TMSBr (34 μ L, 0.26 mmol) in CH₂Cl₂ (1.9 mL) as described in the general procedure afforded the β - (2a, 7.05 mg, 13%) and α -isomer (2b, 8.77 mg, 16%) as white powders. Compound **2a**: ¹H NMR (300 MHz, DMSO- d_6): δ 1.47 (2H, app br s, H-6'a and H-6'b), 1.80 (2H, app br s, H-5'a and H-5'b), 2.13 (1H, app br s, H-2'a), 2.27 (1H, app br s, H-2'b), 3.79 (1H, app s, H-4'), 4.09-4.14 (1H, m, H-3'), 6.14 (1H, app s, H-1'), 7.49-8.27 (8H, m, naphthalene and H-6). ³¹P NMR (DMSO- d_6): δ 20.97. Exact mass (ESI-MS) for C₂₀H₂₀N₂O₇P [M-H]⁻ found: 431.1041, calcd: 431.1014; Compound **2b**: ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.59 (4H, app br s, H-5'a, H-5'b, H-6'a and H-6'b), 1.99–2.06 (1H, m, H-2'a), 2.52–2.70 (1H, m, H-2'b), 4.13 (1H, app s, H-4'), 4.27 (1H, app s, H-3'), 6.18 (1H, app d, I = 5.7 Hz, H-1'), 7.46–7.52 (2H, m, naphthalene), 7.66 (2H, d, I = 8.4 Hz, naphthalene), 7.88-7.91 (3H, m, naphthalene), 8.12(1H, s, naphthalene), 8.31 (1H, s, H-6). ³¹P NMR (DMSO- d_6): δ 24.28. ¹³C NMR (75 MHz, DMSO- d_6): δ 72.61 (C-3'), 85.41 (C-1'), 89.23 (C-4'), 112.48 (C-5), 125.95–132.84 (naphthalene), 139.65 (C-6), 150.02 (C-2), 162.35 (C-4). Exact mass (ESI-MS) for C₂₀H₂₀N₂O₇P [M-H]⁻ found: 431.1009, calcd: 431.1014.

1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)- β -D-hexofuranosyl]-5-(4fluorophenyl)uracil (3a) and 1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)- α -Dhexofuranosyl]-5-(4-fluorophenyl)uracil (3b)

Reaction of compound **16** (36 mg, 0.078 mmol) with TMSBr (21 μ L, 0.16 mmol) in CH₂Cl₂ (1.0 mL) as described in the general procedure afforded the β - (**3a**, 1.69 mg, 6%) and α -isomer (**3b**, 3.19 mg, 12%) as white powders. Compound **3a**: ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.43 (2H, app br s, H-6'a and H-6'b), 1.76 (2H, app br s, H-5'a and H-5'b), 2.09 (1H, app br s, H-2'a), 2.28 (1H, app br s, H-2'b), H-4' under H₂O peak, 4.08 (1H, app s, H-3'), 6.09 (1H, app s, H-1'), 7.21–7.62 (5H, m, subs Ph and H-6). ³¹P NMR (DMSO-*d*₆): δ 20.60. Exact mass (ESI-MS) for C₁₆H₁₇FN₂O₇P [M-H]⁻ found: 399.0762, calcd: 399.0763; Compound **3b**: ¹H NMR (300 MHz, DMSO-*d*₆): δ

1.44–1.58 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 1.99 (1H, d, J = 13.5 Hz, H-2'a), 2.52–2.65 (1H, m, H-2'b), 4.11 (1H, app s, H-4'), 4.20–4.25 (1H, m, H-3'), 6.12 (1H, app d, J = 6.9 Hz, H-1'), 7.19 (2H, app t, J = 8.7 Hz, subs Ph), 7.54–7.59 (2H, m, subs Ph), 8.15 (1H, s, H-6), 8.33 (1H, s, subs Ph). ³¹P NMR (DMSO- d_6): δ 22.19.¹³C NMR (75 MHz, DMSO- d_6): δ 72.22 (C-3'), 85.16 (C-1'), 111.49 (C-5), 114.67, 114.96, 129.57, 129.67 (Ph), 139.00 (C-6), 149.84 (C-2), 162.04 (C-4). Exact mass (ESI-MS) for C₁₆H₁₇FN₂O₇P [M-H]⁻ found: 399.0743, calcd: 399.0763.

1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-hexofuranosyl]-5-(thiophen-2yl)uracil (4a) and 1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-α-Dhexofuranosyl]-5-(thiophen-2-yl)uracil (4b)

Reaction of compound 17 (59 mg, 0.13 mmol) with TMSBr (35 μ L, 0.27 mmol) in $CH_{2}Cl_{2}$ (2.0 mL) as described in the general procedure afforded the β - (4a, 5.2 mg, 10%) and α -isomer (4b, 9.6 mg, 19%) as white powders. Compound 4a: ¹H NMR (300 MHz, DMSO- d_6): δ 1.50 (2H, app br s, H-6'a and H-6'b), 1.80 (2H, app br s, H-5'a and H-5'b), 2.04-2.12 (1H, m, H-2'a), 2.27-2.31 (1H, m, H-2'b), 3.80 (1H, app br s, H-4'), 4.09 (1H, app br s, H-3'), 6.10 (1H, d, I = 6.6 Hz, H-1'), 7.06 (1H, t, I = 4.8 Hz, thiophene), 7.45 (2H, app dd, J = 4.8 Hz, J = 14.4 Hz, thiophene), 7.89 (1H, s, H-6). ³¹P NMR (DMSO- d_6): δ 23.13. ¹³C NMR (75 MHz, CDCl₃): δ (C-6', C-5' and C-2' not visible), 73.42 (C-3'), 85.35 (C-1'), 109.21 (C-5), 123.93, 126.37, 127.43,134.26 (thiophene), 135.74 (C-6), 149.97 (C-2), 161.94 (C-4). Exact mass (ESI-MS) for C₁₄H₁₆N₂O₇PS [M-H]⁻ found:387.0377, calcd: 387.0421; Compound **4b**: ¹H NMR (300 MHz, DMSO- d_6): δ 1.40–1.72 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.02 (1H, app d, I = 14.4 Hz, H-2'a), 2.59–2.68 (1H, m, H-2'b), 4.13 (1H, app d, I = 4.8 Hz, H-3'), 4.27 (4H, app s, H-4'), 6.16 (1H, app d, J = 5.7 Hz, H-1'), 7.04-7.07 (1H, dd, J = 3.6 Hz, J = 4.8 Hz)thiophene), 7.37–7.38 (1H, m, thiophene), 7.44–7.45 (1H, m, thiophene), 8.46 (1H, s, H-6). ³¹P NMR (DMSO-*d*₆): δ 25.63. ¹³C NMR (75 MHz, DMSO d_6): δ 24.29 (C-6', d, J = 135 Hz), 27.01 (C-5'), (C-2' under DMSO peak), 72.59 (C-3'), 85.51 (C-1'), 88.91 (C-4', d, I = 15.7 Hz), 107.71 (C-5), 122.58,125.47, 126.54,134.28 (thiophene), 136.98 (C-6), 149.53 (C-2), 161.87 (C-4). Exact mass (ESI-MS) for C₁₄H₁₆N₂O₇PS [M-H]⁻ found: 387.0416, calcd: 387.0421.

1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-\(\beta-D\)-hexofuranosyl]-uracil (18)

Compound 8 (309 mg, 0.65 mmol) was dissolved in 4.1 mL THF and a TBAF solution in THF (1M, 1.44 mL, 1.44 mmol) was added at rt. After stirring for 3 hours the reaction mixture was evaporated in vacuo and poured on a silica column (CH₂Cl₂/MeOH 92:8) to give compound 18 (162 mg, 69%) as a colorless solid. ¹H NMR (300 MHz, DMSO- d_6): δ 1.23 (6H, t, *J* = 6.9 Hz, 2 x *O*CH₂CH₃), 1.68–1.82 (4H, m, H-5'a, H-5'b, H-6'a and H-6'b), 2.04–2.24 (2H, m, H-2'a and H-2''), 3.66–3.68 (1H, m, H-4'), 3.92–4.08 (5H, m, 2 x *O*CH₂CH₃ and H-3'), 5.30 (1H, d, *J* = 4.5 Hz, 3'-OH), 5.63 (1H, d, *J* = 8.7 Hz, CH=CH), 6.10 (1H, t, *J* = 6.6 Hz, H-1'), 7.58 (1H, d, *J* = 7.8 Hz, CH=CH), 11.31 (1H, s, 3-NH). ³¹P NMR (DMSO-*d*₆): δ 31.89. ¹³C NMR (75 MHz, DMSO-*d*₆): δ 16.26,16.33 (OCH₂CH₃), 21.07 (C-6', d, *J* = 139 Hz), 25.95 (C-5', d, *J* = 4.1 Hz), 60.93, 60.96 (OCH₂CH₃, d, *J* = 6.3 Hz₃, 72.52 (C-3'), 83.65 (C-1'), 85.43 (C-4', *J* = 16.8 Hz), 102.08 (C-5), 140.79 (C-6), 150.45 (C-2), 163.10 (C-4). Exact mass (ESI-MS) for C₁₄H₂₄N₂O₇P [M+H]⁺ found, 363.1308; calcd, 363.1316.

1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)- β -D-hexofuranosyl]-uracil (5a) and 1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)- α -D-hexofuranosyl]-uracil (5b)

To a solution of 18 (40 mg, 0.11 mmol) in CH₂Cl₂ (1.6 mL) was added TMSBr (29 μ L, 0.22 mmol). After stirring overnight, the volatiles were removed in vacuo. The residue was dissolved in water, washed with EtOAc/Et₂O (1:1), and lyophilized. A 3:2 mixture of the α - and β -isomer (25 mg, 65%) was obtained as a yellow powder. ¹H NMR (300 MHz, D₂O): δ 1.48–1.91 (4.4H, m, H-5'a, H-5'b, H-6'a, H-6'b and minor isomer H-2'a), 2.12–2.17 (0.6H, major isomer, m, H-2'b), 2.34–2.38 (0.6H, major isomer, m, H-2'a), 2.72–2.80 (0.4 H, minor isomer, m, H-2'b), 3.94–4.00 (0.4H, minor isomer, m, H-3'), 4.31–4.37 (1.6H, m, major isomer H-3' and H-4'), 5.85 (0.6H, major isomer, d, I = 7.8 Hz, CH=CH), 5.89 (0.4H, minor isomer,d, J = 8.1 Hz, CH=CH), 6.15 (0.6H, major isomer, dd, J = 2.7 Hz, J =7.5 Hz, H-1'), 6.25 (0.4H, minor isomer, app t, J = 6.9 Hz, H-1'), 7.73 (0.4H, minor isomer, d, I = 8.4 Hz, CH=CH), 7.93 (0.6H, major isomer, 10.6H)d, I = 8.1 Hz, CH=CH). ³¹P NMR (DMSO- d_6): δ 23.63. ¹³C NMR (75 MHz, DMSO- d_6): δ 25.53 (major isomer, C-6', d, J = 134 Hz), 27.24 (minor isomer, C-6', d, J = 128 Hz), 72.72 (major isomer, C-3'), 72.86 (minor isomer, C-3'), 83.86 (minor isomer, C-1'), 85.25 (major isomer, C-1'), 87.17 (minor isomer C-4', d, J = 15.2 Hz), 89.09, (major isomer, C-4', d, J = 13.7 Hz), 101.13 (major isomer, C-5), 102.33 (minor isomer, C-5), 140.64 (minor isomer, C-6), 141.67 (major isomer, C-6), 150.62 (minor isomer, C-2), 150.74 (major isomer, C-2), 163.29 (minor isomer, C-4), 163.56 (major isomer, C-4). Exact mass (ESI-MS) for $C_{10}H_{14}N_2O_7P$ [M-H]⁻ found, 305.0539; calcd, 305.0544.

Experimental Assay

Antiviral and Cytotoxicity Assays for Compounds 1a-4b

The antiviral activity of the new compounds was determined using a cytopathogenicity assay against herpes simplex virus type 1 (HSV-1) (KOS

strain), herpes simplex virus type 2 (HSV-2) (G strain), vaccinia virus, vesicular stomatitis virus, HSV-1 TK⁻ KOS ACV^r in HEL cell cultures. Stock solutions of the test compounds were prepared in DMSO at a concentration of 10 mg/mL. Cells, grown to confluency in 96-well plates, were infected with 100 CCID₅₀ of virus, one CCID₅₀ being the 50% cell culture infective dose in the presence of varying concentrations of the test compounds. Cultures were further incubated until complete cytopathogenicity was observed in the infected and untreated virus control. The cytotoxicity of the compounds was evaluated in parallel with their antiviral activity in uninfected cells and is expressed as the minimum cytotoxic concentration (MCC) that causes a microscopically detectable alteration of normal cell morphology. The symbol ">" is used to indicate the highest concentration at which the compounds were tested and found not to be antivirally active."

For the anti-HCMV and anti-VZV assays, HEL fibroblasts were infected with 100 PFU per well. Compounds were added after a 1 hour-incubation period, and the cells were further incubated at 37° C. After 5 (VZV) and 7 days (HCMV) of incubation, plaques (VZV) or virus-induced cytopathogenicity (HCMV) was monitored microscopically after ethanol fixation and staining with Giemsa solution. The cytotoxicity of the compounds was evaluated in parallel with their antiviral activity in uninfected cells and is expressed as the minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology (MCC) and the concentration required to reduce cell growth by 50% (CC₅₀).

Determination of the anti-HIV activity of the compounds was based on virus-induced cytopathogenicity of HIV-infected CEM cells, measured at day 4 to 5 postvirus infection by microscopically estimating virus-induced syncytia formation. The cytostatic activity of the compounds was evaluated in parallel with their antiviral activity in uninfected cell cultures and is expressed as the 50%-inhibitory concentration for the proliferation of the T-lymphocyte CEM cells (EC_{50}).

REFERENCES

- De Clercq, E.; Holý, A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat. Rev. Drug Discov. 2005, 4, 928–940.
- Brulikova, L.; Hlavac, J. Synthesis, reactivity and biological activity of 5-alkoxymethyluracil analogues. Beilstein J. Org. Chem. 2011, 7, 678–698.
- Ivanov, A.V.; Simonyan, A.R.; Belanov, E.F.; Aleksandrova, L.A. Synthesis and antiviral activity of new 5-substituted 2'-deoxyuridine derivatives. *Russ. J. Bioorg. Chem.* 2005, 31, 556–562.
- Wigerinck, P.; Kerremans, L.; Claes, P.; Snoeck, R.; Maudgal, P.; De Clercq, E.; Herdewijn, P. Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues. J. Med. Chem. 1993, 36, 538–543.
- Sastry, J.K.; Nehete, P.N.; Khan, S.; Nowak, B.J.; Plunkett, W.; Arlinghaus, R.B.; Farquhar, D. Membrane-permeable dideoxyuridine 5'-monophosphate analog inhibits humanimmunodeficiency-virus infection. *Mol. Pharmacol.* 1992, 41, 441–445.
- Puech, F.; Gosselin, G.; Lefebvre, I.; Pompon, A.; Aubertin, A.M.; Kirn, A.; Imbach, J.L. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. *Antiviral Res.* 1993, 22, 155–174.

- 7. Fries, K.M.; Joswig, C.; Borch, R.F. Synthesis and biological evaluation of 5-fluoro-2'-deoxyuridine phosphoramidate analogs. J. Med. Chem. 1995, 38, 2672–3680.
- Cosyn, L.; Van Calenbergh, S.; Joshi, B.V.; Ko, H.; Carter, R.L.; Harden, T.K.; Jacobson, K.A. Synthesis and P2Y receptor activity of nucleoside 5'-phosphonate derivatives. *Bioorg. Med. Chem. Lett.* 2009, 19, 3002–3005.
- Rai, D.; Johar, M.; Srivastav, N.C.; Manning, T.; Agrawal, B.; Kunimoto, D.Y.; Kumar, R. Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. J. Med. Chem. 2007, 50, 4766–4774.
- Pomeisl, K.; Holý, A.; Pohl, R. Pd-catalyzed Suzuki-Miyaura coupling reactions in the synthesis of 5aryl-1-[2-(phosphonomethoxy)ethyl]uracils as potential multisubstrate inhibitors of thymidine phosphorylase. *Tetrahedron Lett.* 2007, 48, 3065–3067.
- Van Aerschot, A.; Jie, L.; Herdewijn, P. Synthesis of 5'-O-phosphonomethyl-2',3'-didehydro-2',3'dideoxyuridine by use of P-methoxybenzyl as a N³-protecting group. *Tetrahedron Lett.* 1991, 32, 1905–1908.